viewAlgernon Pharmaceuticals Inc.

Algernon Pharmaceuticals' drug identified by University of Texas as possible coronavirus treatment

Algernon Pharmaceuticals Inc (CSE:AGN) (OTCQB:AGNPF) CEO Christopher Moreau tells Proactive an independent research study by the University of Texas at Dallas has identified its drug Ifenprodil as one of several possible drug candidates to treat the coronavirus disease.

Moreau, who will be speaking directly to investors at Proactive's One2One Investor Conference on July 28th at 1pm EST, says the company’s announcement of the study comes as it plans to launch a multinational Phase 2b/3 human trial of Ifenprodil as a potential therapeutic treatment for COVID-19 sufferers.

Quick facts: Algernon Pharmaceuticals Inc.

Price: 0.31 CAD

Market: CSE
Market Cap: $34.12 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Algernon Pharmaceuticals Inc. named herein, including the promotion by the Company of Algernon Pharmaceuticals Inc. in any Content on the Site,...


Algernon Pharmaceuticals provides update on Phase 2B/3 study as they enroll...

Algernon Pharmaceutical (CSE: AGN-OTCQB: AGNPF) CEO Christopher Moreau joined Steve Darling from Proactive Vancouver with news the company has now enrolled a third of their patients in the Phase 2B/3 study of their repurposed drug Ifenprodil. Moreau discusses hitting that mark and also...

2 weeks, 2 days ago

2 min read